HC Wainwright Issues Pessimistic Forecast for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of Apellis Pharmaceuticals in a report released on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $2.35 for the year, down from their prior forecast of $2.61. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ FY2029 earnings at $3.84 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. During the same period last year, the firm posted ($0.73) earnings per share. The business’s revenue for the quarter was up 45.2% on a year-over-year basis.

Several other brokerages have also recently weighed in on APLS. Bank of America dropped their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company lowered their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Robert W. Baird reduced their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Piper Sandler decreased their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.71.

Apellis Pharmaceuticals Stock Performance

APLS opened at $24.06 on Tuesday. The company’s 50 day moving average is $29.88 and its 200 day moving average is $31.48. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -11.85 and a beta of 0.96. Apellis Pharmaceuticals has a 12-month low of $23.81 and a 12-month high of $66.00.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. True Wealth Design LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Signaturefd LLC boosted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after purchasing an additional 918 shares during the period. Finally, Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $56,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. The trade was a 4.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Cedric Francois sold 6,247 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $179,288.90. Following the transaction, the chief executive officer now owns 307,415 shares of the company’s stock, valued at $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).